OKUR (OnKure Therapeutics, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by OKUR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2026-09-23 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2026-08-13 | Isaac Manke | Director | — | — | — |
| 2026-08-11 | Liam Ratcliffe | Director | A | — | — |
| 2026-08-11 | MICHAEL G GREY | Director | A | — | — |
| 2026-08-11 | Andrew John Phillips | Director | A | — | — |
| 2026-08-11 | Isaac Manke | Director | MIXED | — | — |
| 2026-08-11 | Samuel Agresta | Chief Medical Officer | MIXED | — | — |
| 2026-08-11 | Edward T Mathers | Director | A | — | — |
| 2026-08-11 | Jason A. Leverone | Chief Financial Officer | MIXED | — | — |
| 2026-08-11 | Dylan Hartley | Chief Scientific Officer | MIXED | — | — |
| 2026-08-11 | Nicholas A Saccomano | President and CEO | MIXED | — | — |
| 2026-08-11 | Valerie Malyvanh Jansen | Director | A | — | — |
| 2026-08-11 | R Michael Carruthers | Director | A | — | — |
| 2026-06-24 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2026-06-24 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2026-06-08 | Edward T Mathers | Director | A | — | — |
| 2026-06-08 | Valerie Malyvanh Jansen | Director | A | — | — |
| 2026-06-08 | Liam Ratcliffe | Director | A | — | — |
| 2026-06-08 | Andrew John Phillips | Director | A | — | — |
| 2026-06-08 | R Michael Carruthers | Director | A | — | — |
| 2026-06-08 | MICHAEL G GREY | Director | A | — | — |
| 2026-04-03 | Nicholas A Saccomano | President and CEO | A | — | — |
| 2026-04-03 | Dylan Hartley | Chief Scientific Officer | A | — | — |
| 2026-04-03 | Samuel Agresta | Chief Medical Officer | A | — | — |
| 2026-04-03 | Jason A. Leverone | Chief Financial Officer | A | — | — |
| 2026-04-01 | Liam Ratcliffe | Director | A | — | — |
| 2026-03-24 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2026-03-24 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2026-01-02 | Isaac Manke | Director | A | — | — |
| 2026-01-02 | Edward T Mathers | Director | A | — | — |
| 2025-12-23 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2025-12-23 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2025-10-02 | Edward T Mathers | Director | A | — | — |
| 2025-10-02 | Isaac Manke | Director | A | — | — |
| 2025-09-24 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2025-09-24 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2025-07-02 | Isaac Manke | Director | A | — | — |
| 2025-07-02 | Edward T Mathers | Director | A | — | — |
| 2025-06-25 | Jason A. Leverone | Chief Financial Officer | Sell | — | — |
| 2025-06-25 | Nicholas A Saccomano | President and CEO | Sell | — | — |
| 2025-05-30 | Isaac Manke | Director | A | — | — |
| 2025-05-30 | MICHAEL G GREY | Director | A | — | — |
| 2025-05-30 | Valerie Malyvanh Jansen | Director | A | — | — |
| 2025-05-30 | R Michael Carruthers | Director | A | — | — |
| 2025-05-30 | Andrew John Phillips | Director | A | — | — |
| 2025-05-30 | Edward T Mathers | Director | A | — | — |
| 2025-05-19 | ACORN CAPITAL ADVISORS GP, LLC | 10%+ Owner | Buy | — | — |
| 2025-05-19 | Bihua Chen | — | Sell | — | — |
| 2025-05-14 | Cormorant Private Healthcare Fund IV LP | 10%+ Owner | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,839,674 | — |
| — | 10%+ Owner | 1,813,439 | — |
| — | — | 447,815 | — |
| — | Director | 20,583 | — |
| — | Chief Financial Officer | 18,500 | — |
| — | Director | 15,310 | — |
| — | President and CEO | 11,160 | — |
| — | Director | 4,939 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OKUR quote page; the site-wide leaderboard is on the insider transactions hub.